RxDoctor Payments Data

Larry Allen, MD

Advanced Heart Failure and Transplant Cardiology · Aurora, CONPI 1003913674

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $25,401 of the $31,413 with a category attached, or 80.9%. 11 manufacturers reported payments, led by Boston Scientific at 51.8% of the total. Reporting peaked in 2021 at $10,513 and has fallen 98.7% since, to $140 in 2024.

$31,413in general payments, 2019–2025

Across 49 payments — averaging $641.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$16K
  • Amgen$7K
  • Novartis Pharma AG$7K
  • Abbott$784
  • Paragonix Technologies, Inc.$122
  • Medtronic$80
  • plus $165 from 5 others
$33,327in research payments, 2019–2025

Across 15 payments — averaging $2221.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Quidel Corporation$24K
  • Boston Scientific$9K
  • Ortho-clinical Diagnostics, Inc.$300

What the payments were for

  • Consulting fees$25,40181%
  • Speaking & faculty fees$2,5008%
  • Travel & lodging$2,0326%
  • Food & beverage$1,4795%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Coloradoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$53,014
Medicare patients
247
Services billed
443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis12$184,259
EntrestoSacubitril/Valsartan97$156,524
FarxigaDapagliflozin Propanediol68$93,185
JardianceEmpagliflozin63$84,874
EliquisApixaban40$62,042
VemlidyTenofovir Alafenamide12$15,299
Tacrolimus31$6,823
Eplerenone36$2,653
Metoprolol Succinate116$1,863
Atorvastatin Calcium128$1,454
Potassium Chloride23$1,397
Mycophenolic AcidMycophenolate Sodium15$1,127
Mycophenolate Mofetil18$1,064
Ezetimibe33$1,008
Spironolactone95$893

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$40$156,52497 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Coloradoon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →